Literature DB >> 32437542

Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?

Yagmur Muftuoglu1, Linda M Liau1.   

Abstract

Entities:  

Year:  2020        PMID： 32437542     DOI： 10.1001/jamaoncol.2020.0857

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  A Novel TAF-Related Signature Based on ECM Remodeling Genes Predicts Glioma Prognosis.

Authors:  Lin-Jian Wang; Peipei Lv; Yongli Lou
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

2.  Appropriate Analysis of Duration of Response Data in Cancer Trials.

Authors:  Zachary R McCaw; Lu Tian; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2020-12-01       Impact factor: 31.777

3.  RNA N1-methyladenosine regulator-mediated methylation modification patterns and heterogeneous signatures in glioma.

Authors:  Meng Mao; Qinjun Chu; Yongli Lou; Peipei Lv; Lin-Jian Wang
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

4.  GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.

Authors:  Nga T H Truong; Paris M Kollis; Kristyna Sedivakova; Tessa Gargett; Lisa M Ebert; Wenbo Yu; Erica C F Yeo; Nicole L Wittwer; Briony L Gliddon; Melinda N Tea; Rebecca Ormsby; Santosh Poonnoose; Jake Nowicki; Orazio Vittorio; David S Ziegler; Stuart M Pitson; Michael P Brown
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.